Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Fineline Cube May 6, 2026
Company Drug

AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data

Fineline Cube May 6, 2026
Company Deals

BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province

Fineline Cube Jul 10, 2024

BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...

Company Drug

Shanghai Vitalgen BioPharma Launches Phase I/II Gene Therapy Trial for Parkinson’s Disease

Fineline Cube Jul 10, 2024

Shanghai Vitalgen BioPharma Co., Ltd, a biopharmaceutical company based in China, has initiated a Phase...

Company Drug

Kintor Pharmaceutical Launches Global Cosmetic Line with Hair Loss Treatment Pyrilutamide

Fineline Cube Jul 10, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the global...

Company Drug

Suzhou Sanegene Bio Receives NMPA Approval for Clinical Trial of Antihypertensive siRNA Drug

Fineline Cube Jul 10, 2024

Suzhou Sanegene Bio Inc., a leading RNAi specialist with research and development centers in both...

Company Drug

Shanghai Junshi Biosciences’ HDAC Inhibitor JS125 Clinical Trial Application Accepted by NMPA

Fineline Cube Jul 10, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Drug

Johnson & Johnson’s Opsumit Faces Generic Competition with Qilu Pharmaceutical’s Entry

Fineline Cube Jul 10, 2024

Johnson & Johnson (J&J, NYSE: JNJ)’s pulmonary hypertension treatment, Opsumit (macitentan), is set to encounter...

Company Medical Device

China Isotope & Radiation Corporation Secures NMPA License for Innovative Radiotherapy System

Fineline Cube Jul 10, 2024

China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced that it has received a...

Company

Staidson Pharmaceutical Gets NMPA Green Light for Neurotrophic Keratitis Eye Drop Clinical Trial

Fineline Cube Jul 10, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...

Company

GSK China Vaccine Head Peggy Fung Resigns, Departure Set for Mid-August

Fineline Cube Jul 10, 2024

Peggy Fung, GSK’s Vice President and Head of Vaccine Business in China, has opted to...

Company Deals

GRIT Biotechnology and Quangang Pharmaceutical Co., Ltd Partner to Develop TIL and IL-2 Combination Therapy

Fineline Cube Jul 10, 2024

GRIT Biotechnology, a leading cell therapy specialist based in China, has entered into a strategic...

Policy / Regulatory

US House Speaker Mike Johnson Revives Possibility of Biosecure Act Vote

Fineline Cube Jul 10, 2024

US House of Representatives Speaker Mike Johnson has suggested that a vote on the Biosecure...

Company Drug

Shandong Buchang Pharmaceuticals Receives NMPA Approval for BC008-1A Biologic Product Clinical Trial

Fineline Cube Jul 10, 2024

Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a pharmaceutical company based in China, has announced...

Company Drug

HOB Biotech Receives NMPA Approval for Clinical Trials of MM09 Sublingual Spray

Fineline Cube Jul 10, 2024

Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced that it has received clinical...

Company Deals Medical Device

Hugo Biotech Partners with Watchmaker Genomics to Develop Infectious Disease Detection Solutions

Fineline Cube Jul 10, 2024

Hugo Biotech, a biotech company based in Beijing, has entered into a partnership with Watchmaker...

Company Deals

Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan

Fineline Cube Jul 9, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has...

Company Deals

Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal

Fineline Cube Jul 9, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Company Drug

Roche’s Susvimo Implant Cleared for Relaunch in US After Voluntary Recall

Fineline Cube Jul 9, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced the conclusion of the voluntary recall...

Company Medical Device

Boston Scientific’s FARAPULSE Pulse Field Ablation System Earns NMPA Approval

Fineline Cube Jul 9, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced...

Company Drug

Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment

Fineline Cube Jul 9, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Deals

Keymed Biosciences Strikes Licensing Deal with Belenos Biosciences for Global BsAb Rights

Fineline Cube Jul 9, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a...

Posts pagination

1 … 327 328 329 … 660

Recent updates

  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
  • Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion
  • Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
  • China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026
  • UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Company

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance

Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.